Is Enterococcus, particularly Enterococcus faecalis, a likely cause of infective endocarditis?

Yes, Enterococcus is a Well-Established and Common Cause of Infective Endocarditis

Enterococcus, particularly Enterococcus faecalis, is definitively the third most frequent cause of infective endocarditis globally 1, 2, 3, 4. This is not a rare or unlikely pathogen—it represents a major etiologic agent that clinicians must actively consider when evaluating patients for IE.

Epidemiologic Evidence

The prevalence data are striking and clinically significant:

• In patients with E. faecalis bacteremia, the prevalence of definite IE is 26% when systematic echocardiography (including transesophageal) is performed 3. This high rate was demonstrated in a prospective multicenter study of 344 consecutive patients, making it one of the most robust estimates available.

• Other studies report IE rates of 13-17% in E. faecalis bacteremia when polymicrobial cultures are excluded 5, though rates may be lower (7%) when all bacteremias are included, likely reflecting different patient populations and screening practices.

• The organism typically affects an elderly, fragile population with high mortality rates 4, with 30-day mortality around 29% and 6-month cumulative mortality reaching 55% in some cohorts 6.

Clinical Risk Factors for Enterococcal IE

When E. faecalis bacteremia is identified, specific features dramatically increase IE likelihood 3:

• Prosthetic heart valve (OR 3.93)
• Community acquisition (OR 3.35)
• ≥3 positive blood culture bottles (OR 3.69)
• Unknown portal of entry (OR 2.36)
• Monomicrobial bacteremia (OR 2.73)
• Immunosuppression (OR 2.82)

Important Caveat on Screening

While the high prevalence suggests broad echocardiographic screening, in oncohaematological patients undergoing active treatment, the IE rate drops to only 1% 6. In this specific population, systematic screening may not be warranted and should be individualized based on clinical risk factors (prosthetic valves, persistent bacteremia).

Treatment Implications from Guidelines

Both major guideline bodies provide extensive, specific treatment algorithms for enterococcal IE, which underscores its clinical importance 1, 2:

First-Line Therapy (Beta-lactam and Gentamicin-Susceptible Strains)

• Ampicillin or amoxicillin 200 mg/kg/day IV in 4-6 doses PLUS gentamicin 3 mg/kg/day for 2-6 weeks (Class I, Level B) 2
• Duration: 4-6 weeks for native valve endocarditis (NVE) depending on symptom duration; 6 weeks for prosthetic valve endocarditis (PVE)

Aminoglycoside-Resistant Strains

• Ampicillin 2g IV every 4 hours PLUS ceftriaxone 2g IV every 12 hours for 6 weeks (Class IIa, Level B) 1
• This double beta-lactam regimen is the combination of choice for high-level aminoglycoside-resistant (HLAR) E. faecalis 2
• Critical limitation: This combination is NOT active against E. faecium 2

Penicillin-Allergic or Penicillin-Resistant Patients

• Vancomycin 30 mg/kg/day IV in 2 doses PLUS gentamicin 3 mg/kg/day for 6 weeks (Class I, Level C) 2
• Vancomycin combinations are less active than penicillin/ampicillin combinations and carry higher nephrotoxicity/ototoxicity risk 1

Multidrug-Resistant Enterococci

For vancomycin-resistant strains (fortunately rare in E. faecalis, more common in E. faecium) 1:

• Daptomycin 10 mg/kg/day plus ampicillin
• Linezolid 600 mg IV/PO twice daily for ≥8 weeks (Class IIa, Level C)—monitor for hematologic toxicity 2

Key Clinical Pitfalls

1. Missing the diagnosis: 62% of patients with E. faecalis bacteremia in one cohort did not receive echocardiography 5, likely resulting in missed IE cases

2. Assuming urinary source: E. faecalis bacteremia following urologic procedures (e.g., TURP) may represent IE rather than simple urinary sepsis, especially if symptoms persist despite appropriate therapy 7

3. Monotherapy failure: Enterococci are intrinsically partially resistant to penicillins and ampicillin due to low-affinity penicillin-binding proteins—monotherapy leads to unacceptable failure rates 4. Synergistic combination therapy is mandatory.

4. Species matters: E. faecium has much higher rates of multidrug resistance (95% may be resistant to vancomycin, aminoglycosides, and penicillins) compared to E. faecalis (only 3% multidrug-resistant) 1

5. Renal monitoring: Aminoglycoside levels and renal function must be monitored at least weekly (twice weekly in renal impairment) 2. Elderly patients are particularly vulnerable to nephrotoxicity 8.